p21⁺Trem2⁺ senescent macrophages have been identified as a significant source of chronic inflammation, or inflammaging, in aging and metabolic liver disease. This study utilized both primary mouse and human macrophage models to characterize these cells through multi-omic profiling, revealing a unique expression profile marked by p21 and TREM2. The findings indicate that senescent macrophages not only exhibit a senescence-associated secretory phenotype (SASP) but also are influenced by type I interferon signaling, driven by cytosolic mitochondrial DNA. Notably, the accumulation of these senescent macrophages was observed in aging tissues and metabolic dysfunction-associated steatotic liver disease, highlighting their role in exacerbating liver inflammation.

The implications of this work are profound, as it establishes macrophage senescence as a central mechanism driving chronic inflammation associated with aging. The study demonstrates that senolytic treatments targeting these senescent macrophages can effectively reduce liver inflammation and steatosis in both aged mice and those with metabolic dysfunction. This suggests a potential therapeutic avenue for addressing age-related inflammatory conditions and metabolic diseases, emphasizing the need for further exploration into macrophage-targeted senolytic therapies.

This research shifts the paradigm in aging biology by providing concrete biomarkers to identify senescent macrophages, which can enhance the specificity of senolytic strategies. As the field progresses, these findings could accelerate drug development timelines aimed at mitigating chronic inflammation in aging populations, ultimately contributing to improved healthspan and lifespan outcomes. The study underscores the necessity for continued investigation into the mechanisms of macrophage senescence and its broader implications for age-related diseases.

HealthspanWire tracks this as a research signal: Senolytic therapies are showing clinical efficacy in human trials

Source: nature.com